JP2006517970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517970A5 JP2006517970A5 JP2006503521A JP2006503521A JP2006517970A5 JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5 JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- cancer therapeutic
- antibody
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44771403P | 2003-02-14 | 2003-02-14 | |
| PCT/US2004/004116 WO2004074437A2 (en) | 2003-02-14 | 2004-02-13 | Compositions and methods for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517970A JP2006517970A (ja) | 2006-08-03 |
| JP2006517970A5 true JP2006517970A5 (cg-RX-API-DMAC7.html) | 2007-04-05 |
Family
ID=32908487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503521A Pending JP2006517970A (ja) | 2003-02-14 | 2004-02-13 | 癌免疫療法のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8795672B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1599572A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006517970A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2516028C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004074437A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8795672B2 (en) * | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| CN101072578A (zh) * | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| GB0525535D0 (en) * | 2005-12-15 | 2006-01-25 | Cgt Corp | Tumour treatment |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| US8536310B2 (en) * | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| US11071754B2 (en) * | 2013-03-11 | 2021-07-27 | Case Western Reserve University | Method of generating tumor-specific T cells |
| ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
| WO2015058148A1 (en) * | 2013-10-17 | 2015-04-23 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
| WO2015124297A1 (en) * | 2014-02-19 | 2015-08-27 | Merck Patent Gmbh | Cancer-targeted il-12 immunotherapy |
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| WO2017184873A2 (en) | 2016-04-20 | 2017-10-26 | Aelan Cell Technologies, Inc. | Compositions and methods related to the methylation of histone h1.0 protein |
| US11564944B2 (en) | 2016-11-21 | 2023-01-31 | Nant Holdings Ip, Llc | Fractal combination therapy |
| KR20240148849A (ko) * | 2017-03-20 | 2024-10-11 | 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 | 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체 |
| JP7252953B2 (ja) | 2017-10-25 | 2023-04-05 | エアラン セル テクノロジーズ, インコーポレイテッド | H1.0k180me2抗体、その作製および使用の方法 |
| CN112020516B (zh) | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| WO2020146857A1 (en) * | 2019-01-11 | 2020-07-16 | Arbele Limited | Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof |
| TW202144429A (zh) | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cd25抗體、其抗原結合片段及其醫藥用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116943A (en) * | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) * | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| ATE155482T1 (de) * | 1990-04-06 | 1997-08-15 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT706799E (pt) * | 1994-09-16 | 2002-05-31 | Merck Patent Gmbh | Imunoconjugados ii |
| US5780426A (en) * | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) * | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| GB9814383D0 (en) * | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| US6356619B1 (en) * | 2000-06-02 | 2002-03-12 | General Electric Company | Varying x-ray tube focal spot dimensions to normalize impact temperature |
| MXPA03006587A (es) * | 2001-01-24 | 2003-09-22 | Schering Corp | Quimiocinas como adyuvantes de respuesta inmune. |
| US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| US20030148982A1 (en) * | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US8795672B2 (en) * | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
-
2004
- 2004-02-13 US US10/779,267 patent/US8795672B2/en not_active Expired - Fee Related
- 2004-02-13 EP EP04711085A patent/EP1599572A4/en not_active Ceased
- 2004-02-13 WO PCT/US2004/004116 patent/WO2004074437A2/en not_active Ceased
- 2004-02-13 CA CA2516028A patent/CA2516028C/en not_active Expired - Fee Related
- 2004-02-13 JP JP2006503521A patent/JP2006517970A/ja active Pending
-
2007
- 2007-02-13 US US11/674,569 patent/US8545838B2/en not_active Expired - Fee Related
-
2013
- 2013-04-18 US US13/865,902 patent/US20140099305A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy | |
| DeVita et al. | The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture | |
| Valent et al. | Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML | |
| US10624973B2 (en) | Methods for the depletion of cells | |
| ES2981745T3 (es) | Agentes de señalización biespecíficos y usos de los mismos | |
| CA2926698C (en) | Chimeric antigen receptor t cell switches and uses thereof | |
| Mack et al. | The next generation of antibody drug conjugates | |
| JP2016509582A5 (cg-RX-API-DMAC7.html) | ||
| Quiles et al. | Synthesis and preliminary biological evaluation of high-drug load paclitaxel-antibody conjugates for tumor-targeted chemotherapy | |
| JP2017507936A5 (cg-RX-API-DMAC7.html) | ||
| CA2516028A1 (en) | Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine | |
| WO2006050172A3 (en) | Combination cancer immunotherapy with co-stimulatory molecules | |
| RU2017144606A (ru) | Иммуноцитокины на основе il-15 и il-15rа домена sushi | |
| JP2018510132A5 (cg-RX-API-DMAC7.html) | ||
| JP2025072462A (ja) | 固形および液体悪性病変における多重car t細胞での複数抗原の標的化 | |
| JP2012102122A5 (cg-RX-API-DMAC7.html) | ||
| AR042977A1 (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
| KR20160022370A (ko) | 면역요법을 위한 조성물 및 방법 | |
| Tian et al. | Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone | |
| Safdari et al. | CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies | |
| JP2025527534A (ja) | 抗-ヒト表皮成長因子受容体2(her2)キメラ抗原受容体(car)を含むナチュラルキラー細胞を投与する方法 | |
| JP2006528627A5 (cg-RX-API-DMAC7.html) | ||
| JP2009510165A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Degrader-drug conjugate (DDC) mediated immunochemotherapy for tumor treatment | |
| US12403200B2 (en) | Methods and compositions for treating autoimmune diseases |